Search

Displaying results 3011 - 3020 of 10000 in total
  1. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells.

    Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsSynonyms: Anti-PD-1 monoclonal antibody MGA012
  2. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

    Categories: Programmed Death Ligand-1 Blocker, Programmed Death Receptor-1 Blocking AntibodySynonyms: IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1, *01) (8.8.13) (1-120)-HOMO SAPIENS IGHG1*01 (121-45
  3. Drug

    Anise oil

    go.drugbank.com/drugs/DB15776
    Investigational

    Mixtures: JASIMENTH C PASTILLES, BIOGASTRIN TOZ, 60 G
  4. Drug

    Myrtecaine

    go.drugbank.com/drugs/DB15785
    Investigational

    Mixtures: Algesal 10 %/1 % - Creme, ALGESAL SURACTİVE %10 + %1 MERHEM, 40 GR
  5. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

  6. Drug

    Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15788
    ApprovedInvestigationalWithdrawn

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

    Synonyms: Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)
  7. Drug

    MK-0668

    go.drugbank.com/drugs/DB15791
    Experimental

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Solcoseryl

    go.drugbank.com/drugs/DB15794
    Investigational

    Mixtures: SOLCOSERYL ADHEZIV DIS PATI, 5 GProducts: SOLCOSERYL JELLY 2 g/20 g, SOLCOSERYL OINTMENT 1 g/20 g
  9. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031,A219036]. … It is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Mycobacterium w. Vaccine

    go.drugbank.com/drugs/DB15798
    Investigational

    The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. … As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis.

    Synonyms: Mycobacterium W Vaccine, Mycobacterium w. Vaccine